IP Library Granted Patent US 9,410,103
Granted Patent B2
US 9,410,103 · App. 14/454,538 · Granted Aug 9, 2016

Hydroxy estolides, poly-capped estolides, and methods of making the same

Inventors: Jeremy Forest (Honolulu, HI); Jakob Bredsguard (Lake Forest, CA); Travis Thompson (Anaheim, CA)
Assignee: Biosynthetic Technologies, LLC
C10M105/42C07C69/67C07C69/708C10M105/34C11C3/00C11C3/003C10M2207/301C10N2220/022C10N2220/023C10N2220/027C10N2220/028C10N2220/10C10N2230/02C10N2230/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,410,103
App. No.
14/454,538
Granted
Aug 9, 2016
Kind
B2
Abstract

Provided herein are poly-capped estolides, including those of the Formula IV in which n is an integer equal to or greater than 0; m is an integer equal to or greater than 2; R 1 is selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R 2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; and R 3 and R 4 , independently for each occurrence, are selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched. Hydroxy estolides are also described herein, which may be suitable end products, or serve as intermediates to provide poly-capped estolides. Also provided are compositions containing poly-capped estolides and methods of making both said poly-capped estolides and compositions thereof.

Claims (34)

1. At least one compound according to Formula VI:

wherein

z is an integer selected from 7 and 8;

p is 0;

q is 0;

R 5 and R 6 are independently selected from —C(O)R 1 and an unsubstituted alkyl that is saturated or unsaturated, and branched or unbranched;

R 1 is an unsubstituted alkyl that is saturated or unsaturated, and branched or unbranched; and

R 2 is selected from unsubstituted alkyl that is saturated or unsaturated, and branched or unbranched, and a substituent represented by Formula II:

wherein

x is, independently for each occurrence, an integer selected from 0 to 20;

y is, independently for each occurrence, an integer selected from 0 to 20;

n is 0 to 20;

R 3 is selected from hydrogen and unsubstituted alkyl that is saturated or unsaturated, and branched or unbranched;

W 1 , W 2 , W 3 , W 4 , W 5 , W 6 , and W 7 , independently for each occurrence, are selected from —CH 2 — and —CH═CH—; and

Q 1 , Q 2 , and Q 3 , independently for each occurrence, are selected from hydrogen and —CH 3 ,

wherein each fatty acid chain residue of said at least one compound is unsubstituted.

2. The at least one compound according to claim 1 , wherein R 5 and R 6 are independently selected from —C(O)R 1 .

3. The at least one compound according to claim 2 , wherein R 1 , independently for each occurrence, is selected from an unsubstituted C 1 to C 18 alkyl that is saturated or unsaturated, and branched or unbranched.

4. The at least one compound according to claim 2 , wherein R 1 , independently for each occurrence, is selected from C 5 to C 11 alkyl.

5. The at least one compound according to claim 3 , wherein R 1 is saturated and unbranched for each occurrence.

6. The at least one compound according to claim 1 , wherein R 5 and R 6 are independently selected from C 1 -C 10 alkyl.

7. The at least one compound according to claim 1 , wherein W 3 , W 5 , and W 7 for each occurrence are —CH 2 —.

8. The at least one compound according to claim 7 , wherein W 4 and W 6 for each occurrence are —CH 2 —.

9. The at least one compound according to claim 1 , wherein z is 7.

10. The at least one compound according to claim 1 , wherein R 2 is a substituent represented by Formula II:

11. The at least one compound according to claim 10 , wherein R 3 is selected from optionally substituted C 1 to C 20 alkyl that is saturated or unsaturated and branched or unbranched.

12. The at least one compound according to claim 1 , wherein Q 1 is hydrogen.

13. The at least one compound according to claim 1 , wherein W 3 is —CH 2 — for each occurrence.

14. The at least one compound according to claim 1 , wherein z is 8.

15. The at least one compound according to claim 1 , wherein R 2 is an unsubstituted C 1 -C 18 alkyl that is saturated or unsaturated, and branched or unbranched.

16. The at least one compound according to claim 15 , wherein R 2 is saturated.

17. The at least one compound according to claim 16 , wherein R 2 is an unsubstituted C 6 to C 12 alkyl that is branched.

18. The at least one compound according to claim 13 , wherein R 2 is an unsubstituted C 1 -C 18 alkyl that is saturated or unsaturated, and branched or unbranched.

19. The at least one compound according to claim 18 , wherein Q 1 is hydrogen.

Assignments (6)
ASSIGNMENT OF SECURITY INTEREST Recorded Mar 23, 2018
From: EVONIK OIL ADDITIVES USA, INC.
To: BIOSYN HOLDINGS, LLC
Reel/Frame 045684/0293 →
ASSIGNMENT OF SECURITY INTEREST Recorded Mar 23, 2018
From: BP TECHNOLOGY VENTURES INC.
To: BIOSYN HOLDINGS, LLC
Reel/Frame 045688/0600 →
ASSIGNMENT OF SECURITY INTEREST Recorded Mar 23, 2018
From: EVONIK CORPORATION
To: BIOSYN HOLDINGS, LLC
Reel/Frame 045860/0547 →
SECURITY INTEREST Recorded Jan 30, 2018
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: BP TECHNOLOGY VENTURES INC.
Reel/Frame 045196/0587 →
SECURITY INTEREST Recorded Mar 18, 2016
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: EVONIK OIL ADDITIVES USA, INC.
Reel/Frame 038146/0859 →
SECURITY INTEREST Recorded Nov 30, 2015
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: EVONIK CORPORATION
Reel/Frame 037162/0364 →
Continuity (4)
Continuation 13600704 · Aug 31, 2012
Provisional Application 61529884 · Aug 31, 2011
Provisional Application 61583139 · Jan 4, 2012
Related Publication 20160039739A1 · Feb 11, 2016